Otolaryngology · 2001 · 29 citations · 16 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyDendritic Cell BiologyT Cell Responses To TumorsTumor Immune MicroenvironmentTumor ImmunopathologyAntitumor Immune ActivationDendritic Cell-mediated Antigen Presentation
OBJECTIVES: This study determined whether mobilization of immune inhibitory CD34+ cells by head and neck squamous cell carcinomas (HNSCC) is most prominent in patients who are node positive and whether these CD34+ cells could differentiate into immune stimulatory dendritic cells. STUDY DESIGN AND SETTING: Peripheral blood from patients with head and neck cancer was used to measure the frequency of CD34+ cells and their capacity to differentiate into immune stimulatory dendritic cells. RESULTS: This study demonstrated that increased CD34+ cell levels were most prominent in patients who were node positive and patients with recurrent disease. These CD34+ cells differentiated into dendritic cells that were able to present tetanus toxoid to autologous T-cells. CONCLUSIONS: Immune suppressive CD34+ cells that are prominent in patients with HNSCC who are node positive are able to develop into immune stimulatory dendritic cells. SIGNIFICANCE: Differentiation of tumor-mobilized CD34+ cells into dendritic cells may be an immunotherapeutic approach to stimulate antitumor reactivity.
16
Christophe Caux, Catherine Massacrier, Béatrice Vanbervliet et al. · Blood · 1997 · 421 citations · Full text
Vincenzo Bronte, Dale B. Chappell, Elisa Apolloni et al. · The Journal of Immunology · 1999 · 400 citations · Full text
Life Sciences, Immunology, Oncology +16
A S Pak, Mark A. Wright, J P Matthews et al. · PubMed · 1995 · 272 citations
Life Sciences, Immunology, Oncology +15
Beatrice Schuler-Thurner, Detlef Dieckmann, Petra Keikavoussi et al. · The Journal of Immunology · 2000 · 202 citations · Full text
Medicine, Immunology, Oncology +17